Source: tommaso79/Shutterstock.com Vivos Therapeutics (NASDAQ:VVOS) stock is rocketing higher on Wednesday as investors react to positive news from the U.S. Food and Drug Administration (FDA). The FDA has approved Vivos Therapeutics’ proprietary DNA appliance. This marks it as a Class II device as a new treatment for mild-to-moderate obstructive sleep apnea (OSA). This will have…